OBIO
What one share of Orchestra BioMed Holdings holds
Surgical and Medical Instruments and Apparatus
We are a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. We are led by a highly accomplished, multidisciplinary management team and a board of directors with extensive experience in all phases of therapeutic device development.
Orchestra BioMed Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.54 |
|---|---|
| Profit | −$1.00 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.99 |
| Cash and investments | $1.83 |
| Debt | $0.34 |
| Book value | $0.32 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$0.02 | — | −$0.01 | — | — |
| 2022 | $0.24 | −$2.24 | $0.04 | −$1.99 | — | $2.60 |
| 2023 | $0.08 | −$1.48 | $0.00 | −$1.39 | — | $1.90 |
| 2024 | $0.07 | −$1.66 | $0.01 | −$1.38 | — | $0.86 |
| 2025 | $0.70 | −$1.11 | $0.01 | −$1.04 | — | $0.94 |